Clinical Trial Update: HAIC Combined With Donafenib Tosilate and Toripalimab for Unresectable HCC [Phase 2]

View source ↗

Summary

Phase 2 clinical trial evaluating hepatic arterial infusion chemotherapy (HAIC) combined with donafenib and toripalimab for unresectable hepatocellular carcinom…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Carcinoma

Drugs mentioned

• Donafenib Tosilate (donafenib)
• HAIC (hepatic arterial infusion chemotherapy) (hepatic arterial infusion chemotherapy)
• Toripalimab (Toripalimab)

Snippet

Sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University | Conditions: Hepatocellular Carcinoma | Phase 2 | Status: UNKNOWN